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ABSTRACT
The development of a universal influenza vaccine is an ideal strategy to eliminate public
health threats from influenza epidemics and pandemics. Influenza conserved structures are
outstanding immunogens for such a vaccine. Layered protein nanoparticles composed of welldesigned conserved influenza structures have improved immunogenicity with new physical and
biochemical features. We constructed and purified structure-stabilized influenza matrix protein 2
ectodomain (M2e) and M2e-neuraminidase fusion proteins (M2e-NAs). We produced doublelayered M2e-NA protein nanoparticles by chemical crosslinking M2e-NA onto M2e nanoparticle
surfaces. Immunizations with these protein nanoparticles induced immune protection against
influenza viruses with homologous and heterosubtypic NA in mice. Double-layered M2e-NA
protein nanoparticles induced higher levels of humoral and cellular responses compared with their
comprising protein mixture or M2e nanoparticles. In addition, the layered M2e-NA protein
nanoparticle group demonstrated strong cytotoxic T cell responses. We also found that antibody
responses contributed to heterosubtypic influenza viral immune protection. The protective
immunity was long-lasting.
To favorite rapid distribution and convenient administration of a universal influenza
vaccine, we incorporated the FliC-adjuvanted M2e-NA nanoparticles into logistically simple
microneedle patches (MNPs) for skin vaccination in mice. The nanoparticle MNPs significantly
increased M2e and NA-specific antibody levels, the numbers of germinal center B cells, and IL-4
secreting splenocytes. MNPs incorporating the double-layered nanoparticles protected mice
against homologous and heterosubtypic influenza viruses. Our results demonstrated that M2e-NA
nanoparticles could be developed into a standalone or synergistic component of a universal

influenza vaccine strategy. MNP skin vaccination can logistically simplify the vaccines for
extensive distribution and administration.
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INTRODUCTION
Influenza continuously poses a severe public health risk and causes pandemics. Another severe
influenza pandemic is inevitable and just a matter of time [1, 2]. Current seasonal influenza
vaccines can effectively protect healthy adults against well-matched strains, but mismatches
frequently occur because of the high rate of antigenic variation in influenza surface antigens [3].
For instance, during the 2014-2015 influenza season, the overall vaccine effectiveness was very
low, estimating an adjusted 19% in the US because the major circulating H3N2 viruses drifted
from the vaccine strain [4]. The 2017-2018 flu season is another case of a severe outbreak of an
influenza epidemic since 2009 due to a weak vaccine efficacy versus the prevalent H3N2 strain
[5, 6]. Beyond epidemics, a non-human influenza virus could acquire mutations gaining the
capacity for effective transmission in humans and result in an influenza pandemic [7, 8]. The
outcome of such a pandemic would be catastrophic because humans have no historical immunity
to such viruses.
A universal influenza vaccine will negate the need for yearly influenza vaccinations and serve as
a countermeasure against the emergence of novel pandemic strains by offering universal
protection. Multiple approaches have been investigated - the promising ones utilize epitopes that
are conserved across different influenza virus strains as the vaccine immunogens [9-11]. However,
conserved antigens (such as the ectodomain of influenza M2 protein or HA stalk domains)
generally induce weak immune responses and require adjuvants to boost their potency. Delivery
of protein antigens is also a challenge because of their fast degradation and diffusion upon
introduction to the body.
Our laboratory has studied solid protein nanoparticles (nanoclusters) as a universal influenza
vaccine delivery system in recent years. In this study, the protein nanoparticles comprised of
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almost conserved antigenic proteins like Neuraminidase (NA), Matrix ectodomain (M2e), and a
minimal amount of a reducible crosslinker. Moreover, to further simplify the vaccine for extensive
distribution and convenient administration, we incorporated the flagellin (FliC)-adjuvanted
nanoparticles into microneedle patches (MNPs) for painless skin vaccination.
1.1

Conserved influenza epitopes for universal influenza vaccines

The influenza virion has two highly glycosylated proteins, HA and NA, and a third ionic channel
protein, M2 on its surface. Influenza virus infection can cause severe respiratory disease during
the yearly influenza seasons by evading prevailing immunity via frequent mutations on the
globular head of the hemagglutinin protein (HA). In recent years, the researchers focused more on
the conserved structures from NA or M2 in developing a universal influenza vaccine [12].
1.1.1 The glycoprotein neuraminidase in influenza virus
Influenza neuraminidase (NA) is an important membrane glycoprotein containing four identical
polypeptides. Although NA facilitate the influenza viral replication during the virus entry, receptor
binding, and virus internalization, the most characterized function of NA is its catalytic activity
of cleaving sialic acid and HA. Inside the catalytic site of NA, the inner eight highly conserved
residues directly interact with sialic acid, while ten outer conserved residues do not contact sialic
acid but provide space for the substrates [13]. Among the eight highly conserved residues, the
Tyr406 is crucial for the catalytic function as a nucleophile [14]. The conserved feature of catalytic
site makes NA an ideal target for anti-viral drug development.
For a long time, NA was underestimated by the vaccinology community due to its relatively poor
immunogenicity and the immunodominance of HA[15]. However, recent studies have shown NA
to be a promising antigen for vaccine development: (1) Compared with HA, NA experiences
relatively slower antigenic drift [16]. (2) A universally conserved NA epitope between 222-230
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induced NA-inhibiting antibodies against all influenza types[17, 18]. (3) Therapeutic NA-specific
monoclonal antibodies protected mice from lethal doses of homologous and heterologous inﬂuenza
infection[19]. Most NA antibodies do not directly neutralize the influenza virion but inhibit
enzymatic activity [20]. Moreover, the non-neutralizing NA-antibody inhibit the influenza virus
by FcRs mediated antibody-dependent cellular cytotoxicity (ADCC) [21]. For example, a 2009
pandemic H1N1 strain derived NA-reactive antibody, 3C05, required FcγRs during protection
[22]; the H3N2 derived mAbs 1G04 can protect mice against various type of influenza virus
including influenza B/Malaysia/2004 and avian virus H4N6 [23]. These discoveries demonstrated
that NA has the potential to be developed into a universal influenza vaccine if it is presented in an
immunogenic form, such as protein nanoparticles.
1.1.2 The ectodomain of the M2 protein (M2e)
Although much less abundant than HA, M2 is an essential protein that functions in viral assembly
and morphogenesis. Upon the binding of HA to sialic acid of host cells, receptor-mediated
endocytosis occurs and the whole endosome is acidified with a downregulated pH to 5 to 6. The
acidic environment enable the M2 proton channel open and result in the proton influx to the virion.
Then the viral ribonucleoprotein (RNP) complexes are released into the cytoplasma for the entry
to nucleus [24]. The M2 extracellular domain (M2e) contains a highly conserved amino acid
sequence, SLLTEVET, which is over 99% conserved among all subtype A influenza viruses [25,
26]. Compared with HA, the natural M2e is weakly immunogenic. To improve the weak
immunogenicity, researchers usually combine this epitope with more immunogenic components
like HA or increase the copy number of the highly conserved sequence in the tetrameric structure
[27, 28].
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Moreover, nanoparticles are another option to improve the immunogenicity of M2e
because the conserved epitope can be loaded at high density and co-loaded with immune
stimulators. For example, a fusion protein compromised of M2e, helix C of the hemagglutinin stalk
domain (from H1N1 PR8 or H5N2 Penn), a universal T cell epitope, and flagellin was created.
Under the right chemical conditions, the fusion protein self-assembled into 24-mer nanoparticles
which carried the antigens above in their native conformations [29]. Antibody titers induced in
chickens by the flagellin-adjuvanted H5N2 HA stalk domain nanoparticles conferred broad crossprotection. The H1N1 PR8 nanoparticles protected mice from a lethal dose challenge, while the
mice in an inactivated virus vaccine-immunized group showed limited protection. The ferritin cage
structure to carry three tandem repeats of M2e was adapted. This 3M2e-ferritin nanoparticle
induced balanced Th1/Th2 immune responses, a long-term humoral response, and long-lived M2especific lymphocytes [30]. Intranasally administered 3M2e-ferritin nanoparticles induced a
predominantly secretory IgA at the mucosal surfaces and fully protected the immunized mice
against challenges by lethal homosubtypic human H1N1 and heterosubtypic H9N2 avian influenza
viruses.

1.2

Advantages of nanoparticle vaccine platforms in the development of influenza
vaccine

1.2.1 The safety of nanoparticle vaccines
To apply a vaccine in clinical use, guaranteeing safety for the immunized population is critical. A
stricter discipline related to vaccine development was applying to older adults and young children
[31, 32]. Current inactivated virus vaccine candidates were from egg or cell-based production, and
the whole influenza viruses were harvested and inactivated by formaldehyde[33]. The production
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flow allowed the possibility that egg-allergic patients were sensitive to this type of vaccine [34].
Meanwhile, the split and whole inactivated influenza virus vaccine still possess potential risk
because of the replication possibility of the retained influenza virion genome. The fusion proteins
or peptides were secreted or anchored by host cells and thus avoid containing egg components.
New nanoparticle vaccines only consist of pure fusion proteins or peptides, with no virion DNA
or RNA. For example, a very common baculovirus system can be used in expressing recombinant
M2e based virus-like particles[28]; co-assembling peptides (CAPs) spontaneously assembled to a
nanoparticle by the interaction of hydrophobic and hydrophilic residues[35]. These two strategies
provide a safe route to make a particle without viral genomes.
1.2.2 Reducing the complexity of designing a nanoparticle
In the generation of nanoparticles from protein modules, each nanoparticle possesses its own
process flow or protocol for production. From the point of the production complexity, fabricating
polymer-based or desolvated nanoparticles is easier than VLPs and self-assembly nanoparticles.
To construct VLPs or self-assembly nanoparticles, several factors should be considered during
designing. (1) Whether the chimeric VLP protein can be secreted by host cells. Hence, to
successfully construct the influenza VLP, researchers usually adapted M1 from the influenza virus
as the intracellular domain and thus limited the antigen combination. (2) Whether the peptide can
be self-folded to a protein nanoparticle. To form a symmetry pattern, fusion proteins of two
oligomerization domains preferring a-helical conformation should be held together at a right angle
and in a rigid fashion [36]. When designing a self-assembly peptide, researchers should consider
the structure of amino acids from influenza antigen and obey the roles of constructing peptidebased building blocks into discrete morphologies [37].
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The novel physicochemical-driven protein nanoparticle vaccines adapted the following
manufacturing strategy: (1) concentrating a protein solution with polar solvents (such as ethanol)
to form a particulate protein core; and (2) crosslinking other proteins onto the core by using a
reversible crosslinker such as 3,3'-Dithiobis(sulfosuccinimidylpropionate) (DTSSP) [38]. In this
study, two distinct proteins (Neuraminidase and M2e protein) with natural structures have been
expressed and crosslinked by using this strategy.
1.2.3 Effectively displaying neuraminidase and M2e antigen in layered protein nanoparticles
Core/shell layered protein nanoparticles effectively display antigens in two aspects: a. increase the
number of authentic neuraminidase and M2e antigen molecules in nanoparticles; b. broaden the
antigen combination of influenza antigens.
a. One of the current self-assembly nanoparticles adapted ferritin as the core structure protein to
load the influenza antigen. However, the non-specific effect (off-target) of the vaccine was induced
because a significant antibody level against ferritin can be found in immunized mice. [39]. Our
novel physicochemical-driven protein nanoparticles consist of two natural antigens
(Neuraminidase and M2e protein), which avoid introducing the exogenous protein and prevent the
off-target effect.
b. Most proteins in solution can be desolvated by adding desolvation reagents such as natural salt
or organic solvent (methanol, ethanol, etc.): the proteins solute could aggregate into nanoparticles
after removing the original solvent [40]. Because the naked desolvated protein nanoparticles can
further crosslink with different proteins sequentially on their surfaces, multiply layered protein
nanoparticles can be fabricated to accommodate different antigens for differential antigenprocessing and presentation for a synergistic immune response. In other words, these two antigens
in nanoparticles are convertible: either M2e core or coated neuraminidase can be switched to other
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antigens from influenza virion, and the combination is arbitrary. Thus, the layered protein
nanoparticles broaden the antigen combination pool and increase the number of possible influenza
vaccine candidates.
1.2.4 Extended storage period at room temperature
Vaccine storage is one crucial issue for maintaining antigen immunogenicity. Usually, in highincome countries, the cold chain industry is mature and well developed. However, in many lowincome countries, the need for storage is not optimal because of the shortage of electricity and
insufficient funding for cold chain equipment [41].
The layered protein nanoparticles improved the storage time. The influenza-based hemagglutinin
(H7) nanoparticles maintained the intact shape and size to more than 3 months at 25°C. Such
nanoparticles were also stable for 2 weeks at 37°C. Moreover, the warm-aged nanoparticle did not
lose hemagglutinating activity and thus induced high anti-HA titer in boost-immunized mice as in
the fresh nanoparticle group [42]. With this stability, the physicochemical-driven protein
nanoparticles would be a promising vaccine technic to low-income countries outside of the cold
chain.
1.3

Microneedle patches encapsulating flagellin-adjuvanted nanoparticles

1.3.1 The application of flagellin in vaccine development
FliC is the major structural protein of Gram-negative bacteria ﬂagella and a potent adjuvant [43].
Toll-Like Receptor 5 (TLR-5) recognizes FliC and initiates an innate signaling cascade. The
consequence includes the generation of transcription factor NF-κB and subsequent gene
expression, such as TNF-α. Previous studies have added FliC to different antigen combinations to
increase dendritic cell (DC) cytokine and chemokine production, maturation, and antigenprocessing/presentation. FliC could also enhance the protection breadth of the influenza vaccines.
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For example, while H1/M1 VLPs conferred no protection to H3N2, FliC-adjuvanted H1/M1 VLPs
effectively improved heterosubtypic protection against H3N2 [44-46]. We have expressed 4M2etFliC and 4M2e-HA stalk fusion proteins as standalone vaccines or as supplements to improve the
immunity breadth of inactivated vaccines [38].
However, a high dose of a flagellin-M2e fusion protein (STF2.4M2e) vaccination generated an
overproduction of inflammatory molecules in a clinical trial [47]. Conversely, a lower amount (0.5
µg) of FliC-adjuvanted HIV VLPs induced significantly higher levels of neutralizing antibody
responses than non-adjuvanted VLPs without abnormal symptoms seen [48]. In the present work,
we are using a flexible and controllable DTSSP crosslinking method to introduce FliC onto the
surface of the M2e core nanoparticles to enhance immune responses while minimizing the side
effects of FliC.
1.3.2 The advantage of the application of microneedle patches
Microneedles are a new delivery platform for drugs, including vaccines targeting skin
administration. This technology delivers immunogens directly to dendritic cells and epidermal
Langerhans cells in the epidermis and dermis [49]. After absorbing immunogens, dendritic cells
in the dermis migrate to draining lymph nodes and activate the expansion of T cells [50].
Langerhans cells in the dermis cross-present immunogens and have anti-tumor and anti-viral roles
[51]. Skin vaccination by microneedle patches has displayed many advantages over traditional
intramuscular vaccination and is an improved delivery method. Skin vaccination focuses on
antigen-presenting cells by delivering immunogens to T cells or B cells near draining lymph nodes.
Compared to intramuscular vaccination, microneedle patches enlargen the contact surface of
immunogens and immune cells and increase immune efficiency. Finally, immunization by
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microneedles is significantly less painful than intramuscular vaccination [52] and can be easily
handled by healthcare providers or even by patients themselves [53].
Researchers have also studied encapsulating nanoparticles or VLP in microneedles in hopes of
enhancing protection. Zaric et al. encapsulated PLGA with OVA and delivered these PLGA
nanoparticles into the dermis of mice. The study demonstrated strong antigen-specific immune
responses. Quan et al. stabilized PR8 VLPs in microneedles by adding trehalose disaccharide.
These stabilized microneedles induced high titers of IgG2a and 100% protection against a lethal
viral challenge, which was superior to intramuscular or unstabilized microneedles [54]. Moreover,
microneedle delivered PR8 VLPs induced long-lasting (14 months after a single immunization)
lung IgG and IgA responses, increased antibody-secreting splenocytes, and conferred protection
to elderly mice [55]. Kim et al. constructed a tandem M2e repeat (M2e5x) VLP, which elicited
IgG2a and IFN-γ secreting cell response and protected mice against heterosubtypic H1N1, H3N2,
and H5N1 influenza virus challenges via a microneedle delivery route. The M2e-5x VLP dissolved
microneedle was stable for eight weeks at room temperature [56]. In one of our recent studies,
dissolvable microneedle patches encapsulated with NP polypeptide or NP protein nanoparticles
demonstrated robust CD8+ T cell responses [57].
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2

SPECIAL AIMS

Influenza, a type of negative-sense, single-stranded RNA virus, belonging to the family of
Orthomyxoviridae, presented a real threat to public health annually. The current seasonal influenza
vaccine confers only limited protection due to the antigenic shift and drift of major influenza
surface antigens. A universal influenza vaccine that induces broad cross-protection against
different viruses will negate annual vaccinations and protect against possible influenza pandemics.
The extracellular domain (M2e) of the influenza matrix protein 2 (M2) contains a highly conserved
amino acid sequence. Its 8 N-terminal amino acid residues (SLLTEVET) is over 99% conserved
among all subtype A influenza viruses [25]; another influenza surface glycoprotein, neuraminidase
(NA) contains highly conserved epitopes that have elicited universal anti-NA antibodies against
all sub-types of influenza A [17].

A novel layered protein nanoparticle platform based on a core/shell orchestration is a highly potent
vaccine platform. We found that M2e can be assembled into a particulate core by ethanal
desolvation. A shell layer can be subsequently formed onto the core surface with influenza
hemagglutinin (HA), or the globular head removed HA protein. Such double-layered nanoparticles
induced broad protection against various viruses crossing different subtypes in mice [58]. In this
study, we investigated whether a layered protein nanoparticle of M2e core/M2e-NA shell
(designated M2e-NA Nano) can be constructed to induce broadly reactive immune responses in
mice, functioning as a standalone or complementary component together with other immunogens
in a future universal influenza vaccine. Moreover, skin vaccination with the FliC-adjuvanted
NA/M2e nanoparticles by MNPs contributed to the generation of germinal centers, maturation of
B cells, and induced robust humoral and cellular immune responses specific to M2e and NA. These
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enhanced immune responses translated into broad cross-protection against the influenza viruses of
homologous and heterosubtypic NA.

Aim 1: Determine whether enhanced protection will be conferred by M2e-NA Nano
1a: Generate and characterize M2e-NA Nano vaccines containing M2e and NA (four tandem
repeat M2e and transmembrane domain removed NA protein)
1b: Determine the immunogenicity and protective efficacy of M2e-NANP vaccines in mice

Aim 2: Determine mechanisms of M2e-NANP in conferring protection in mice
2a: Determine the protective efficacy of M2e-NA Nano in heterosubtypic protection
2b: Determine detailed T cell responses of M2e and NA contributing to protection and efficacy
2c: Determine the impacts of novel vaccination on long-term protection

Aim 3: Determine the improved protection and immunological mechanisms of NA-FliC/M2e
MNP induced protection in mice
3a: Determine whether NA-FliC/M2e nanoparticle (MFNA) can be incorporated to microneedle
patches (MNPs)
3b: Determine the immunogenicity of MFNA MNP in mice
3c: Determine the protective efficacy of MFNA MNP in homogeneous and heterosubtypic
protection
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3
3.1

EXPERIMENT DESIGN AND RESULTS

Part I Double-layered M2e-NA Nanoparticles induce protection against divergent
influenza viruses

3.1.1 Aim 1: Determine whether enhanced protection will be conferred by M2e-NA Nano
1a: Generate and characterize M2e-NA Nano vaccines containing M2e and NA (four tandem
repeat M2e and transmembrane domain removed NA protein)
To fabricate effective immunogenic M2e-NA Nano, the selection of representative M2e or
Neuraminidase is essential.
Rationale: (1) Currently, H1N1 and H3N2 influenza viruses are circulating in humans in flu
seasons. Influenza neuraminidases have been divided into groups 1 with N1, N4, and N8 subtypes
and group 2 covering N2, N3, N6, N7, and N9 [59]. Therefore, N1 and N2, the typical
neuraminidases from two groups in phylogeny, can be chosen for the out-layer antigen of M2eNA Nano.
(2) Compared to HA, M2e has weak immunogenicity. Researchers usually combine the epitope
with higher immunogenic protein to overcome this weakness, like HA, or repeat the highly
conserved sequence in tetrameric structures to increase the immunogenicity [27, 28]. In summary,
as an excellent carrier, nanoparticles can be loaded with the conserved epitopes in the desired way
for inducing a cross-protection against different subtypes of influenza viruses.
For the construction of the tetrameric M2e protein expressing vector, encoding sequences of a
honeybee melittin signal peptide, a hexahistidine tag, a tetrameric motif tetrabrachion [60], and
four tandem copies of different M2e were fused in-frame and subcloned into the transferring vector
pFastBac for recombinant baculovirus (rBV) generation.
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For the construction of the M2e-NA fusion protein-expressing vector, encoding sequences of
neuraminidase 1 and 2 ectodomains [61] (N1 from A/Vietnam/1203/2004 (Viet, H5N1, Genbank
Accession EF541467 (36H to 449K); N2 from A/Aichi/2/1968 (Aichi, H3N2, Genbank Accession
AB295606 (38K to 469I)) were fused to the above tetrameric M2e encoding gene in-frame. The
resulting tetrameric M2e-NA encoding genes were cloned into pFastBac and used to generate rBVs
expressing M2e-NA fusion proteins.
We constructed genes encoding targeted conserved antigens (M2e, M2e-N1 fusion protein, and
M2e-N2 fusion protein) (Figure 1A), generated recombinant baculoviruses (rBVs) with these
genes, and expressed and purified the recombinant proteins in insect cells. Results from SDSPAGE followed by the Coomassie blue staining and Western blotting analysis demonstrated that
the proteins were purified to high purity, appearing as a major band in gel staining (Figure 1B),
and the protein identities were confirmed by antigen-specific antibody detection in the Western
blots (Figure 1B).
We generated M2e protein nanoparticles by ethanol desolvation as previously described [58]. In
brief, the M2e core particles were formed by slowly adding a 4-fold volume of ethanol to a volume
of M2e solution in PBS while stirring. The coating layer of M2e-NA fusion proteins was
crosslinked onto the M2e cores using 3′-dithiol bis [sulfosuccinimidylpropionate] (DTSSP; Cat
No. 21578, Thermo Scientiﬁc, Waltham, MA). After one and a half hours of incubation for the
crosslinking reaction, the nanoparticle-containing supernatant was centrifuged at 15,000 rpm for
30 minutes. We collected the nanoparticle pellet, resuspended the pellet in PBS, and stabilized the
nanoparticle suspension by sonication at a 40% amplitude on an iced-both. The size and surface
potential of the layered M2e-NA protein nanoparticles were measured by dynamic light scattering
(DLS) analysis with a Malvern Zetasizer Nano ZS (Malvern Instruments, Westborough, MA). Bis
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[sulfosuccinimidyl] (BS3) crosslinking followed by the Western blotting analysis were performed
to determine the polymeric state of the purified recombinant M2e and M2e-NA fusion proteins. A
10% SDS-PAGE followed with the Coomassie blue staining was applied for the characterization
of the M2e-NA nanoparticle compositions. The ratio of M2e-NA to M2e protein was measured
using GelQuantNET software after Coomassie blue staining. Monoclonal antibody 14C2 (Thermo
Fisher Scientific, Cat. # MA1-082) was used for the confirmation of the M2e epitope in the M2eNA nanoparticles.
Double-layered M2e-N1 or M2e-N2 nanoparticles were generated by coating M2e-N1 or M2e-N2
fusion proteins onto the surfaces of M2e nanoparticles with dithiobis (sulfosuccinimidyl
propionate) (DTSSP) crosslinking (diagramed Figure 1C). The Coomassie blue staining and
Western blotting analysis demonstrated the M2e and NA composition of the layered protein
nanoparticles (Figure 1D). The size ranges of the resulting double-layered protein nanoparticles
were 211.0 +/- 60.14 nm and 190.4 +/- 53.52 nm for M2e-N1 and M2e-N2 nanoparticles,
respectively (Figure 1F, M2e-N1 Nano and M2e-N2 Nano). In comparison, the M2e core
nanoparticle size was 176.4 +/- 48.3 nm (Figure 1F, M2e Nano). The layered M2e-N1 and M2eN2 protein nanoparticles showed negative ζ-potentials of -27.77 +/-1.16 mV and -21.03 +/- 0.93
mV, and the loading ratios of M2e-N1 and M2e-N2 to the total protein in their layered protein
nanoparticles were 62.1% +/- 2.5% and 59.3% +/- 1.8%, respectively. Neuraminidase activity
assays showed the retention of NA activity in the resulting layered M2e-NA nanoparticles (Figure
1E). Transmission electron microscopy (TEM) observation further revealed the roughly spherical
shape of the layered protein nanoparticles with irregular surfaces (Figure 1G).
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Figure 1. The fabrication of double-layered M2e-NA protein nanoparticles.
A. Diagrams of M2e and M2e-NA fusion proteins and their coding sequence compositions. GS
linker: glycine and serine GGSGGG; M2e: a recombination of four tandem M2e sequences from
human, swine, avian, and domestic fowl influenza viruses stabilized by the tetrabrachion
tetramerization sequence; M2e-N1 fusion protein: sequence of NA ectodomain (36H to 449K from
Viet (H5N1) NA) fused with the four tandem M2e repeats and stabilized by the tetrabrachion
sequence; M2e-N2 fusion protein: as M2e-N1 but the sequence of NA ectodomain is from Aichi
(H3N2) NA(38K to 469I). B. Characterization of purified recombinant proteins with Coomassie
blue staining. Line 1, recombinant M2e; Line 2, M2e-N1; Line 3, M2e-N2. C. Diagrams of layered
protein nanoparticle generation. M2e protein nanoparticles (M2e Nano) were generated by
ethanol desolvation. Double-layered M2e-N1 and M2e-N2 protein nanoparticles (M2e-N1 Nano
and M2e-N2 Nano) were formed by crosslinking M2e-N1 and M2e-N2 fusion proteins onto the
surfaces M2e Nano as coatings, respectively. D. Coomassie blue staining and western blotting of
protein nanoparticles in a SDS-PAGE gel. Line 1, double-layered M2e-N1 protein nanoparticles; Line 2,
double-layered M2e-N2 protein nanoparticles. E. Neuraminidase activity. NA activity was acquired by
using ELLA as described in Materials and Methods. The concentration of M2e-N1 nanoparticle, M2e-N2
nanoparticle, Vietnam virus, or Aichi virus was 1mg/mL (total protein). F. The size range of protein
nanoparticles. Red, M2e-N1 Nano; Green, M2e-N2 Nano; Blue, M2e Nano. G. TEM image of doublelayered M2e-NA nanoparticles. All types of protein nanoparticles have a similar morphology. The image
was acquired using double-layered M2e-N2 protein nanoparticles as an example. Bar scale, 500 nm.

1b: Determine the immunogenicity and protective efficacy of M2e-NANP vaccines in mice
Six to eight-week-old BALB/c mice from Jackson Laboratory were used for the immunization and
challenge experiments (n=5). There were five mouse groups for each M2e-NA nanoparticle group
set: (1) PBS; (2) M2e-NA layered nanoparticle (10 μg total protein with ~6 μg of M2e-NA in the
outer layer and ~4 μg of M2e in the core); (3) soluble M2e and soluble M2e-NA protein mixture
(a dose of 10 μg total protein with 6 μg M2e-NA and 4 μg M2e); Mice received primary and boost
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immunizations at a four-week interval by an intramuscular route. Immune sera were collected 21
days after the boost immunization.
Because the full-length NA will be loaded to the nanoparticles, it is of interest to investigate
whether epitopes in NA or M2e protein will significantly activate the B cell response. Moreover,
IFN-γ promotes the differentiation of Th1 CD4 T cells and thus increases the IgG2a secretion [62];
IL-4 increases the proliferation of Th2 CD4 T cells and promotes the IgG1 secretion [63].
Therefore, we want to examine whether the M2e-NANPs induce the correlated cellular immune
response by specific NA or M2e epitopes.
Unlike the NA protein in live influenza viruses or inactivated vaccines, the NA fusion proteins on
the surfaces of the layered protein nanoparticles were at high density and were not shielded by
other larger immunogenic proteins, such as HA. We hypothesized that these traits made the NA
fusion proteins highly immunogenic in the nanoparticles. Immune serum antibody titrations
showed that the double-layered nanoparticle immunizations significantly increased NA and M2especific IgG antibody levels (the total serum IgG, as well as the IgG1 and IgG2a subtypes)
compared with the soluble protein mixture immunization groups (sM2e+NA) (Figure 2A and C).
Mice in the layered M2e-NA nanoparticle groups produced significantly higher M2e and NAspecific IFN-γ secreting splenocytes after the boost immunization (Figure 2B and D).
Because the neuraminidase inhibition (NAI) of immune sera is a correlate of NA mediated immune
protection, we performed an NAI test to show the neutralizing ability of immune sera from every
group[64]. Sera from the layered M2e-N1 nanoparticle and M2e-N2 nanoparticle groups showed
potent neutralization to both homologous and heterologous NA influenza viruses. The M2e-N1
nanoparticle immune sera showed a significant decrease in OD450nm (indicating an elevated NAI)
compared with the sM2e+N1 (soluble protein mixture) immune sera up to a 20,480-fold dilution.

18
The layered M2e-N2 nanoparticle sera showed a significant decrease up to a 32,000-fold dilution
in OD450nm compared with the corresponding soluble protein mixture or untreated N2 virus (Aichi,
or A/Hong Kong/99 (Hong Kong, H9N2)) NA activity (Figure 2E and F). However, immune sera
from layered M2e-N1 or M2e-N2 nanoparticle groups showed lower levels of NAI activity against
the heterosubtypic NA influenza viruses. Layered M2e-N1 nanoparticle immune sera showed a
significant decrease in OD450nm compared with the untreated Aichi/68 virus NA activity down to
a 640-fold dilution while M2e-N2 nanoparticle sera showed a significant decrease in OD450nm
compared with the untreated A/California/2009 (Cal, H1N1, the 2009 pandemic strain) virus NA
activity down to only a 500-fold dilution (Figure 2E and F).
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Figure 2. Humoral and cellular immune responses of vaccinated mice.
A. Detection of NA-specific antibody responses by ELISA. Neuraminidase 1 (NA1) from Viet and
Neuraminidase 2 (NA2) from Aichi were coated on the 96-well plates and sera from different groups were
tested. B. Enumeration of NA-specific IFN-γ secreted splenocytes by ELISpot. The spleens of boost
immunized mice were collected before the influenza challenge and N1 or N2 peptide pools were added to
the homogenized splenocytes for stimulation. C. M2e-specific antibody responses. M2e peptide was coated
on the 96-well plates and sera from different groups were tested for anti-M2e titers. D. Enumeration of
M2e activated IFN-γ secreted splenocytes by ELISpot. The spleens of boost immunized mice were collected
before the influenza challenge and M2e peptide pools were added to the homogenized splenocytes for
activation. E and F. NAI test against different strains of influenza viruses. Sera from the M2e-N1 group set
(E) were mixed with 8000 TCID50 rViet (H5N1), Cal (H1N1), and Aichi (H3N2). The OD450 value was
measured by using ELLA. The OD values have been compared with the virus only and naive serum reads.
The end dilution titers of sera for the maximum significant inhibition are as follows: rViet (H5N1), 20480;
Cal (H1N1), 20480; Aichi (H3N2), 640. Sera from the M2e-N2 group set (F) were mixed with 8000 TCID50
Aichi (H3N2), Hong Kong (HK, H9N2), and Cal (H1N1). The end dilution titer of sera for the maximum
significant inhibition is as follows. Aichi (H3N2): 32000, Hong Kong (H9N2): 32000, Cal (H1N1): 500.
Data represent mean ± SEM. The statistical significance was analyzed by a two-tail unpaired t-test (n=5;
*, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, p > 0.05).

We challenged mice in the layered M2e-N1 nanoparticle group with doses of 3× LD50 of the
reassortant A/Vietnam/1203/2004 (rViet, H5N1, PR8 backbone with HA and NA from Viet), or
5× LD50 Cal and mice in the M2e-N2 nanoparticle group with doses of 5× LD50 of Aichi (H3N2)
or Hong Kong (H9N2) viruses to verify immune protection against homologous or heterologous
viral infection (Figure 3). Mice receiving the M2e-N1 or M2e-N2 nanoparticle immunizations
completely survived their respective NA virus challenges (Figure 3A and B). Mice receiving the
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soluble sM2e+N1 immunization had a 100% survival rate against the rViet challenge, but the
sM2e+N2 immunization demonstrated partial protection against the homologous viral challenge
(Figure 3A and B). The nanoparticle immunization groups tended to lose less bodyweight than
the soluble protein immunization groups, with the Hong Kong (H9N2) viral challenge being an
exception (Figure 3).
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Figure 3. Immune protection against homologous and heterologous NA virus challenge.
A. Bodyweight monitoring and survival rate of M2e-N1 group set against the challenge of 3×LD50 rViet
(H5N1); B. Bodyweight monitoring and survival rate of M2e-N2 group set versus 5×LD50 Aichi (H3N2)
challenge. C. Bodyweight monitoring and survival rate of M2e-N1 group set versus 5×LD50 Cal (H1N1)
challenge, D. Bodyweight monitoring and survival rate of M2e-N2 group set versus 5×LD50 Hong Kong
(H9N2) challenge. Data represent mean ± SEM. The difference in survival rates between different groups
was analyzed by Graphpad Prism, using the Log-rank test. (n=5; *, p < 0.05; **, p < 0.01; ns, p > 0.05).

Furthermore, the layered protein nanoparticle immunization groups had significantly reduced viral
titers in the lungs compared with the soluble protein groups five days after the homologous viral
challenges. (Figure 4A). Histological examinations of the lung tissue from the challenged mice
indicated that layered protein nanoparticle groups showed a lower degree of immune cell
infiltration and inflammation near the alveolar walls compared to the sM2e-NA soluble protein
mixture groups, but the naïve control mice presented a heavier inflammatory state and severe tissue
damage (Figure 4B).
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Figure 4. Lung viral titers and histology of M2e-N1 and M2e-N2 group sets.
A. Viral titers of lungs from different immunization groups at 5 days after the infection. B. Histology
examination by using H&E staining. Arrows show tissue damage and alveolar epithelium infiltration.
Data represent mean ± SEM. The statistical significance was analyzed by the two-tail unpaired t-test.
(n=5; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, p > 0.05.)

3.1.2 Aim 2: Determine mechanisms of M2e-NANP in conferring protection in mice
2a: Determine the protective efficacy of M2e-NA Nano in heterosubtypic protection
There was low NAI against heterosubtypic influenza strains in previous studies [65], here we
included the M2e antigen to enhance the heterosubtypic protection. We have found that protein
nanoparticles with M2e inner cores triggered strong T cell immune responses contributing to the
overall cross-protective immunity. The protein nanoparticles of conserved influenza antigens
preferentially induced non-neutralizing antibody responses [58]. The protection upon the passive
serum transfer indicated that the M2e-specific antibody responses might confer protection via
antibody-dependent cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADPC), as
previously observed [66].
We tested the cross-protection of the nanoparticles against heterosubtypic virus challenges.
Because NA fusion proteins in this study are derived from N1 in Viet (H5N1) and N2 in Aichi
(H3N2), 3×LD50 of A/Philippines/2/82 (Philippines, H3N2) was applied to the M2e-N1
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nanoparticle immunization cohort while 5×LD50 of Cal (H1N1) was applied to the M2e-N2
nanoparticle immunization cohort to test the heterosubtypic protection. Immunized mice in the
M2e-N1 nanoparticle group showed a 100% survival against the Philippines virus challenge while
the sM2e+N1 soluble protein mixture induced partial protection (Figure 5A). M2e-N2
nanoparticle immunized mice showed a 60% survival against the Cal virus challenge while mice
from the corresponding sM2e+N2 soluble protein group, as well as naïve mice, reached their
endpoints at day 7 post the challenge infection (Figure 5B).
5 mice from each group received the prime and boost immunization as described previously. After
the boost immunization, mice serum from 4 groups in M2e-N1 or M2e-N2 team will be collected.
Serum from different groups has been mixed with the same volume of H1N1 or H3N2 influenza
virus and incubated on the 96-well plate with Fetuin and the Neuraminidase inhibition test was
performed.
Passive transmission of immune sera can show the immunological role of the antibodies without
T cell responses. To verify whether the immune sera from the M2e-NA nanoparticle group confer
cross-protection against heterologous influenza viruses, we intraperitoneally injected naïve mice
with 300 μL sera from double-layered protein nanoparticle-immunized mice 24 hours before the
challenge infection. Sera from M2e-N1 nanoparticle and M2e-N2 nanoparticle immunized mice
conferred enhanced protection against rH5N1 and H3N2 influenza virus infection as shown by
100% survivals and preventing severe body weight loss, respectively (Figure 6C, M2e-N1 Nano;
Figure 6D, M2e-N2 Nano). Meanwhile, immune sera from sM2e+N1 and sM2e+N2 soluble
protein-immunized mice showed weaker protection than their corresponding layered protein
nanoparticles, demonstrated by significantly more severe morbidity in the soluble protein mixture
groups upon challenge (Figure 6C, sM2e+N1; Figure 6D, sM2e+N2). These results demonstrated
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that serum antibody responses contributed to the heterosubtypic protection in the layered protein
nanoparticle immunization.

Figure 5. Immune protection against heterosubtypic NA virus challenge.

A. M2e-N1 group set versus the challenge of 5×LD50 Philippines (H3N2). B. M2e-N1group set
versus the challenge of 5×LD50 Cal (H1N1). C and D, body weight changes of mice upon passive
immune serum transfers. Immune sera (300 μL) from layered M2e-N1 protein nanoparticle or
sM2e+N1 immunized mice were I.P. injected into mice 24 hours before the challenge infection
with 3×LD50 Aichi (C). Immune sera (300 μL) from layered M2e-N2 protein nanoparticle or
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sM2e+N2 immunized mice were I.P. administered to mice 24 hours before the 3×LD50 rViet
challenge infection (D). Bodyweight changes were monitored for 14 days post the challenge.
Data represent mean ± SEM. The statistical significance of survival rate was analyzed by Graphpad Prism,
using the Log-rank test (n=5; *, p < 0.05; **, p < 0.01; ns, p > 0.05.)

2b: Determine detailed T cell responses of M2e and NA contributing to protection and efficacy
NA has been known to induce both CD4 and CD8 T cell responses[67]. Upon influenza infection,
both CD8+ CTL and CD4+ helper T cells differentiate and proliferate into effector cells with the
increasing IFN-γ secretion [68]. In our previous studies, we have found protein nanoparticles with
M2e inner cores triggered strong T cell immune responses contributing to the overall crossprotective immunity [58]. Thus, we want to further investigate the T cell responses to NA or M2e.
We compared different T cell responses induced by double-layered M2e-NA nanoparticles and
sM2e+NA protein mixtures. CD4 T cells facilitate B cell differentiation and maintenance of CD8
cytotoxic T cell response, while CD8 T cells have a role in viral clearance from the lungs [69].
The layered M2e-N1 nanoparticle immunization significantly increased the number of IFN-γ
secreting CD4 and CD8 T cells in the lungs five days after the rViet (H5N1) infection (Figure 6A,
B, E, and F). The layered M2e-N2 nanoparticle immunization induced even stronger T cell
responses, demonstrated by higher numbers of IFN-γ secreting CD4 and CD8 T cell populations
in the lung five days after the Aichi (H3N2) challenge infection (Figure 6C, D, E, and F). In
contrast, the soluble protein mixture immunization did not show significant T cell population
activation upon the challenge infection of homologous NA influenza viruses (Figure 6A and B,
sM2e+N1 verse the rViet challenge; Figure 6C and D, sM2e+N2 verse the Aichi challenge).
To investigate whether the CD8 T cell responses correlate with the immune protection, we depleted
CD8 T cells from M2e-NA nanoparticle immunized mice by injecting 300 μL anti-CD8 antibody
clone 2.43 (Cat no. BE0061; BioXCell) 24 hours before and after the challenge infection. CD8 T
cell depletion groups showed a greater body weight loss and a decreased survival rate over
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immunized groups without the depletion (Figure 6G and H). We observed that double-layered
M2e-NA protein nanoparticles increased the populations of effector T cells secreting IFN-γ. The
protection of M2e-NA nanoparticle-immunized mice was impaired after CD8 T cell depletion demonstrating M2e and NA-specific CTL responses contribute to the protection observed in the
study. We concluded that NA-specific T cell responses, in addition to M2e T cell responses, played
an important role in the protein nanoparticle-induced cross-protection. These results indicated that
layered M2e-NA protein nanoparticles conferred immune protection at least partially through CD8
T cell responses against influenza infection.

27

28

Figure 6 T cell responses in M2e-NA nanoparticle immunized mice.

Characterization of T cell response by selected cell markers with FACS. After stimulation by N1
or N2 peptides, the homogenized lung cells were stained by antibodies against CD3, CD45, CD4,
CD8, and intracellular cytokines IFN-γ. Lymphocytes were marked by selecting CD3, CD45+
gated cells. A. CD4+, IFN-γ+ T cells; B. CD8+, IFN-γ+ T cells. Cells were stimulated with an N1
peptide pool. C. CD4+, IFN-γ + T cells; D. CD8+, IFN-γ+ T cells. Cells were stimulated with an
N2 peptide pool. E, F. Percentages of INF-γ-secreting CD8 T cells (E) and CD4 T cells (F) were
acquired from flow cytometry data in Figure 6A to D. G. T cell depletion assay of M2e-N1
nanoparticle immunized mice versus 3×LD50 H5N1. H. T cell depletion assay of M2e-N2 nanoparticle
immunized mice versus 5×LD50 H3N2. Data represent mean ± SEM. The statistical significance was
analyzed by the two-tail unpaired t-test, and the survival rate between different groups was analyzed by
Graphpad Prism, using Log-rank test (Num=5, * p < 0.05, ** p < 0.01, ns p > 0.05.)

2c: Determine the impacts of novel vaccination on long-term protection
When developing a vaccine, scientists expect more about persistent efficacy. Moreover, elder
people are susceptible to influenza infection because of immunosenescence [70]. Therefore, a
long-lasting immune response is a necessary feature for an ideal vaccine. Here, we evaluated the
longevity of the immunity induced by the double-layered protein nanoparticle formulations. We
immunized mice with M2e-N1 nanoparticles, M2e-N2 nanoparticles, or soluble M2e and M2eNA proteins twice with a 4-week interval. After four months, we collected the immune sera from
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the mice. Immunized mice in both double-layered M2e-NA protein nanoparticle groups
maintained significantly higher M2e- and NA-specific antibodies than the soluble protein mixture
groups (Figure 7A and B).
We then challenged the layered M2e-N1 protein nanoparticle-immunized mice with rViet (H5N1)
and the layered M2e-N2 protein nanoparticle-immunized mice with Aichi (H3N2). The immune
protection of the nanoparticle group was unchanged against the viral challenges up to 4 months
after the immunizations. Furthermore, the double-layered protein nanoparticle immunizations
limited morbidity significantly than the soluble protein immunizations (Figure 7C and D).
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Figure 7. Long-term immune protection.
A and B. long-term antigen-specific antibody binding titers. M2e-specific (A) and NA-specific (B)
antibody titers in immune sera from mice 4 months after boost immunizations were measured by ELISA.
C and D. Long-term immune protection. M2e-N1 group set was challenged with 3×LD50 rViet 4 months
after the boost immunization (C). M2e-N2 group set was challenged with 3×LD50 Aichi 4 months after
the boost immunization (D). Data represent mean ± SEM. The statistical significance was analyzed by the
two-tail unpaired t-test, and survival rates were analyzed by Graphpad Prism, using Log-rank test (n=5;
*, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, p > 0.05.).

3.1.3 Conclusion
In conclusion, the double-layered M2e-NA protein nanoparticles were highly immunogenic,
inducing broadly reactive immune responses against both M2e and different NA antigens. The
induced immunity conferred protection against viruses of different NA subtypes. Both antibody
and T cell immune responses contributed to cross-protection. Our results showed that doublelayered M2e-NA protein nanoparticles had the potential to be developed into influenza universal
vaccines, either alone or as a synergistic component in more complicated influenza universal
vaccine formulations. The incorporation of stabilized antigenic proteins into layered protein
nanoparticles could be a general vaccine strategy for different pathogens.
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3.2

Part II Skin vaccination with dissolvable microneedle patches incorporating influenza
neuraminidase and flagellin protein nanoparticles induces broad immune protection
against multiple influenza viruses

3.2.1 Aim 3: Determine the improved protection and immunological mechanisms of NAFliC/M2e MNP induced protection in mice
3a: Determine whether NA-FliC/M2e nanoparticle (MFNA) can be incorporated to microneedle
patches (MNPs)
For Neuraminidase (NA) construction, a honeybee melittin signal peptide, a tetrameric motif
tetrabrachion, and hexahistidine tag were preserved from the previous M2e-NA nanoparticle
project [71]. The sequences of transmembrane removed Neuraminidase 1 and 2 were followed
behind the tetrabrachion sequence. For the M2e protein expression vector, we kept the previous
construct as in the M2e-NA nanoparticle project [71]. For FliC gene construction, the ﬂagellin
gene (ﬂiC; GenBank accession no. D13689) was ligated into the pet-22b(+) vector. (Figure.1.A)
After the generation of recombinant baculoviruses (rBVs) encoding the extracellular domain of
M2 (M2e), neuraminidase1 (NA1), and neuraminidase2 (NA2), the M2e, NA1, and NA 2 protein
have been expressed and purified. The FliC protein was also purified from a bacterial protein
expression as previously described [38]. The purified NA1, NA2, and FliC proteins showed major
bands in the Coomassie Blue gel staining and Western blotting results, respectively (Figure. 1B).
Previously, the FliC has been purified either in fused status with influenza antigen or co-expressed
within virus-like particles (VLP) [38, 45]. DTSSP could crosslink its sulfo-NHS-ester to primary
amines in the side chain of lysine (K) residues in FliC and M2e protein core [72]. Our lab
successfully crosslinked the HA-FliC or M2e-FliC fusion protein onto the M2e core. The resulting
self-adjuvanted nanoparticle fully protected mice from a lethal dose of influenza viral challenge
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[38]. We fabricated double-layered N1-FliC/M2e and N2-FliC/M2e nanoparticles (designated as
MFN1 and MFN2) by using the DTSSP crosslinking method as diagramed in Figure.1C. The
Coomassie blue staining confirmed the M2e, NA, and FliC composition of the layered protein
nanoparticles (Figure.1D, MFN1, MFN2). Protein components in double-layered nanoparticles
were confirmed by using anti-His, FliC, or M2e antibodies (Figure.1D).
The resulting double-layered protein nanoparticles had particle sizes in a range of 150-250 nm
(MN1, 195.8 +/- 26.2 nm; MN2, 213.4 +/- 27.6 nm; MFN1, 245.6 +/-20.5 nm; and MFN2, 223.5
+/- 15.6 nm. Figure 1E). The polydispersity index (PDI) of four nanoparticles is less than 0.2. All
layered protein nanoparticles showed negative ζ-potentials: MN1, −27.76 +/−1.19 mV; MN2,
−21.26 +/− 0.98 mV; MFN1, -26.5+/- 1.01 mV; MFN2, -22.36 +/- 0.43 mV. Transmission electron
microscopy (TEM) observation revealed the roughly spherical shape of the layered protein
nanoparticles (Figure 1E). MFN1, MFN2, or soluble FliC protein, stimulated 293T cells (with
transfection of plasmids containing TLR5 and NF-ĸB-luciferase reporter genes) to produce
comparable levels of TLR5 innate signal as demonstrated by their similar RLUs [73] (Figure 1F).

33

34

Figure. 1 The characterization of double-layered NA-FliC/M2e and NA/M2e protein
nanoparticles.
A. Diagrams of M2e, NA, and Flagellin fusion proteins and their coding sequence compositions.
GS linker: glycine and serine GGSGGG; M2e: recombination of four tandem M2e sequences from
human, swine, avian, and domestic fowl influenza viruses stabilized by the tetrabrachion
tetramerization sequence; NA1 recombinant protein: the sequence of NA ectodomain (36H to
449K from Viet (H5N1) NA) fused and stabilized by the tetrabrachion sequence; NA2 recombinant
protein: as NA1 fusion protein but the sequence of NA ectodomain is from Aichi (H3N2) NA (38K
to 469I). FliC: the full-length ﬂiC gene followed by 6x His-tag.
B. Coomassie blue staining of purified NA1 (N1), NA2 (N2), and FliC recombinant proteins.
C. Diagrams of layered MFN generation. M2e protein nanoparticles (M2e Nano) were generated
by ethanol desolvation. Double-layered NA1-FliC/M2e- and NA2-FliC/M2e-protein nanoparticles
(MFN1 and MFN2) were formed by crosslinking NA1, NA2, and FliC proteins onto the surfaces
M2e core as coatings, respectively. D. Coomassie blue staining and Western Blot analysis of the
fabricated MFN1 and MFN2 nanoparticles. E. Left panel, The size range of protein nanoparticles.
Right panel, TEM images of MFN1 and MFN2. Bar scale: 200 nm. F. TLR5-specific bioactivity of
MFN1, MFN2, and soluble FliC.

The skin is the largest immune organ with high populations of dermal dendritic cells (DCs)
[74, 75]. Our nanoparticles target skin dendritic cells for optimal DC maturation by MNP skin
vaccination. We observed an increased fluorescence intensity in JAWS II cells - a dendritic cell
line originated from mouse bone marrow - incubated with AF488-labeled MFN1 nanoparticles
compared with a soluble protein mixture of AF488-labeled M2e, NA1, and FliC (designated
sMFN1) (Figure 2A, MFN1 vs. sMFN1). MFN1 nanoparticles significantly increased the
fluorescence intensity 1 hour after incubating with JAWS II cells. Meanwhile, the soluble protein-
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treated group showed substantially fewer cells with positive AF488 signals (Figure 2A). These
results demonstrate that DCs could effectively internalize double-layered protein nanoparticles.
We further evaluated whether protein nanoparticles induced DC maturation. Because IL-6
and TNF-α cytokines can trigger DC maturation via an autocrine fashion [76, 77], we measured
the secretion levels of these two cytokines by JAWS II cell or primary bone marrow dendritic cells
(BMDC) culture after treatments with different antigens. FliC significantly elevated the IL-6 and
TNF-α production by JAWS II cells (Figure 2B, C, sMN1 vs. sMFN1).
The nanoparticle groups induced substantially higher IL-6 and TNF-α levels than the
soluble protein mixture groups. The nanoparticle group without FliC triggered comparable
cytokine production to soluble FliC, demonstrating the adjuvant efficacy of the protein
nanoparticles themselves. The FliC-containing nanoparticle group produced the highest cytokines
(Figure 2B, C, JAWS II cells, sMFN1 vs. MN1 group). In BMDCs, both MN1 and MFN1
nanoparticles induced significantly higher levels of IL-6 and TNF-α than the soluble protein
mixture groups (Figure 2B, C, MN1 and MFN1 vs. sMFN1). These data demonstrated that
nanoparticles induced higher expression of IL-6 and TNF- α by DCs.
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Figure 2. In-vitro internalization of MFN1 nanoparticles by dendritic cells.
A. Fluorescence images of JAWS II cells incubated with Alexa Fluor 488-labeled soluble
M2e and NA1 or MN1 or MFN1. The fluorescence intensity of AF488 was counted using mean
fluorescence intensity (MFI). Bar scale, 50 µm. B, C. Cytokines (IL-6 and TNF-α) secretion in
JAWS II cells or BMDCs treated with soluble M2e and NA1 (sMN1), soluble M2e, NA1, and
FliC (sMFN1), MN1, and MFN1 at a concentration of 5 µg/mL. (n = 5; **p < 0.01; ***p <
0.001; ns, p > 0.05)

The skin vaccination strategy with MNP has been applied to improve vaccine delivery and
immunogenicity. Abundant DCs and macrophages resident within the skin’s dermis can be
targeted by MNP administration [78]. The microneedle length in this study was 650 μm, which
can fully cross the stratum corneum to deposit antigens into the viable epidermis and superficial
dermal layer [79]. Dissolved MNP skin vaccination prolonged the in vivo kinetics of antigen
release, enabling the observation of nanoparticles in the application site up to 14 days after
immunization [80]. The intermediately sized nanoparticles (around 100-200nm) diffused slowly
from the MNP insertion site and were transported within the more permeable regions of the
extracellular matrix [81], which allowed more time for antigen-presenting cells capture. It has been
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well established that prolonged antigen availability contributes to the formation of GCs, leading
to enhanced antibody responses [80]. Four types of MNPs encapsulating different nanoparticles
(MN1, MN2, MFN1, and MFN2) were fabricated as described previously [79]. After MNP
administration to mice, Western blotting results showed that less than 30% of M2e and 20% of
NA were retained in the microneedle bases (Figure 3A). These results indicated that MNP skin
vaccination delivered 70%-80% of the MNP-loaded nanoparticles.
High-affinity antibody production is closely related to antigen persistence, B cell receptor
somatic hypermutation, and B cell affinity maturation in germinal centers (GCs) [82]. CD95 and
GL7 double-positive GC B cell populations were determined in ILNs on day 7 after one
immunization. As shown in Figure 3B and C, after MFN2 MNP immunization, there were
significantly increased numbers of B220+CD95+GL7+ GC B cells in ILNs compared with the other
groups. The MN2 MNP-immunized group also showed a higher B220+CD95+GL7+ population
than the sMFN2 or PBS group. Therefore, MNP skin vaccination induced enhanced germinal
center reactions.
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Figure 3. Vaccine-delivery efficacies of MNPs and germinal center immune responses
A. A magniﬁed view of the structure and layout of the MNP before and after attaching to the skin.
Bar scale, 1.0 mm. Determination of remaining M2e-N1 nanoparticles in MNPs after sticking to
the skin using anti-his antibody with the Western Blot method. B, C. Germinal center B cell
responses in vaccinated mice. The percentage of CD95 and GL7 positive cells from inguinal lymph
nodes 7 days after the primary immunization-. (n = 3; * p<0.05, **p < 0.01; ***p < 0.001; ns, p
> 0.05)
3b: Determine the immunogenicity of MFNA MNP in mice
We designed the different vaccination groups to consider IM vs. MNP delivery, soluble protein
vs. nanoparticle antigens, and FliC vs. no FliC. As shown in Figure 4A, B, the MFN1 MNP
immunization induced the highest M2e and NA1-specific antibody responses among the five
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groups in the M2e-NA1 group cohort. In contrast, MN2 and MFN2 MNP immunizations induced
similarly high levels of M2e and NA2-specific antibody responses in the M2e-NA2 group cohort.
Neuraminidase inhibition (NAI) of immune sera correlates to NA-mediated immune protection
[83]. Our NAI assay results showed that immune sera from MN1 and MN2 groups possessed
potent neutralization to homologous NA influenza viruses. MFN1 and MN1 MNP and MN1 IM
immune sera showed a significant decrease in OD450 (indicating an elevated NAI) compared with
sMFN1 immune sera or untreated NA1 virus (Figure 4C, H5N1) up to a 20,480-fold dilution.
MFN2 and MN2 MNP immune sera showed a similar inhibition, at a 20,480-fold dilution, in OD450
compared with untreated NA2 virus (Figure 4C, H3N2).
IL-4 mediates the differentiation of naïve T cells into Th2 cells and the differentiation and
proliferation of B cells, driving immunoglobulin(Ig) class switching to IgG1 and memory B cell
production [84, 85]. We determined the IL-4 secreting cell population at week three after boosting
immunization. The MFN1 and MFN2 MNP immunizations significantly increased the numbers of
M2e and NA-specific IL-4 secreting splenocytes in each group (Figure 4D, E).
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Figure 4. Humoral and cellular immune responses in vaccinated mice.
A. M2e-specific antibody responses. B. NA-specific antibody responses. C. NA inhibition test
against H5N1 or H3N2. D, E. Enumeration of M2e or NA activated IL-4 secreting splenocytes
by ELIspot. (n = 5; * p<0.05; **p < 0.01; ***p < 0.001; ns, p > 0.05)

3c: Determine the protective efficacy of MFNA MNP against homogeneous and
heterosubtypic virus challenges
To determine immune protection against homologous viral infection, we challenged mice in the
M2e-NA1 group with 5× LD50 reassortant A/Vietnam/1203/2004 (rViet, H5N1) and mice in the
M2e-NA2 group set with 5× LD50 of Aichi (H3N2) (Figure 5). Mice receiving the MN1-MNP,
MFN1-MNP, MFN1-IM or MN2-MNP, MFN2-MNP, MFN2-IM immunizations completely
survived their corresponding NA virus challenges (Figure 5A and C). Mice receiving the soluble
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sMFN2 immunization showed a 50% survival rate against the rViet challenge and partial
protection (40% survival rate) against the homologous viral (Aichi) challenge (Figure 5A and C).
To determine if the immunity protected mice against heterosubtypic NA virus, we challenged mice
in the M2e-NA2 group cluster with 5× LD50 PR8 (H1N1) and the M2e-NA1 group cluster with 5×
LD50 of Aichi (H3N2). Mice receiving skin MNP vaccination (MN1, MFN1, MN2, and MFN2
MNP groups) showed 100% survival. Mice receiving MFN1 or MFN2 IM vaccination resulted in
an 80% survival rate to H3N2 or a 50% survival rate to the challenge of H1N1, respectively. Mice
immunized with sMFN1 or sMFN2 showed a 50% survival rate to the challenge of H3N2 and
H1N1, respectively (Figure 5B and D). The FliC-adjuvanted group (MFN MNP) displayed a
quicker bodyweight recovery than the non-adjuvanted group (MN MNP) and an increased survival
rate compared with the MFN IM group in the heterosubtypic NA influenza challenge.
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Figure 5. Immune protection against influenza viruses with homologous and heterosubtypic
NA.
A, B. Bodyweight monitoring and survival rate of NA1-Flic/M2e group set. Challenge dose: A.
5×LD50 rViet (H5N1); B. 5×LD50 Aichi (H3N2). C, D Bodyweight monitoring and survival rate
of NA2-Flic/M2e group set. Challenge dose: C. 5×LD50 Aichi (H3N2) challenge; D. 5×LD50
PR8 (H1N1). (* p<0.05, **p < 0.01; n = 5).

Lung tissues from all the challenged mice were histologically analyzed. The MNP and IM
nanoparticle groups showed less alveolar inflammation and less immune cell infiltration than the
naïve infection or soluble protein mixture groups (Figure 6A, B). Consistent with the decreased
injury scores in the layered protein nanoparticle immunized groups, all MNP skin immunization
groups showed significantly reduced viral titers in the lungs than the corresponding soluble protein
mixture groups (Figure 6C).
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Figure 6. Histology examination and lung viral titers
A. Histology examination by using H&E staining. Bar scale, 100 µm. B. Lung injury scores of
H5N1 and H3N2 infected groups. C. Viral titers of lungs from different immunization groups. (n
= 5; * p<0.05; **p < 0.01; ***p < 0.001)
Interferon-gamma (IFN-γ) is mainly produced by CD4 T cells and acts as a critical mediator in
cellular immunity. IFN-γ is required for effector CD4 T cells to mediate lung protection and
necessary for host survival [86, 87]. Antigen-specific IFN-γ-secreting CD4 T cells were analyzed
after viral challenges. Compared with the MN2-MNP, MFN2-IM, and sMFN2-IM groups, MFN2MNP immunization significantly increased the percentage of M2e and NA2-specific IFN-γsecreting CD4 T cells in lungs five days after Aichi (H3N2) infection. However, only a moderate
increase of NA2-specific IFN-γ-secreting populations was observed after MN2 MNP
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immunization. The results indicate that FliC in nanoparticle MNP skin vaccination plays a vital
role in inducing antigen-specific IFN-γ secretion (Figure 7A, B).

Figure 7. IFN-γ secreting CD4 T cell responses post-infection
A. B. The percentage of IFN-γ secreting CD4 T cells from lungs of mice infected by 1× LD50 of
H3N2. (n = 3; * p<0.05; **p < 0.01; ***p < 0.001; ns, p > 0.05)

3.2.2 Conclusion
In summary, we have successfully fabricated layered protein nanoparticles made of relatively
conserved influenza NA and M2e and a molecular adjuvant FliC. The introduction of FliC
increased the antigen capture, cytokine secretion, and maturation of dendritic cells. Compared with
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traditional intramuscular immunization, the MNP skin vaccination efficiently delivered antigens
to skin antigen-presenting cells, inducing robust NA- and M2e-specific antibody or cellular
responses. Therefore, the combination of MNP skin vaccination with MFN protein nanoparticles
conferred protection against homologous and heterosubtypic NA viral infection. The selfadjuvanted MFN protein nanoparticles administered to the skin have the potential to be further
developed into a standalone universal influenza vaccine or as part of a synergistic, multicomponent vaccine for broad protection against influenza.
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CONCLUSION

In summary, we have successfully fabricated layered protein nanoparticles made of
relatively conserved influenza NA and M2e and a molecular adjuvant FliC. The introduction of
FliC increased the antigen capture, cytokine secretion, and maturation of dendritic cells. Our
results show that double-layered M2e-NA protein nanoparticles have the potential to be developed
into influenza universal vaccines, either alone or as a synergistic component in more complicated
influenza universal vaccine formulations. Previous studies indicated that Antibody-dependent
cellular cytotoxicity (ADCC) was mediated by NA or M2e specific antibodies using Fc resceptors.
Both ADCC intermediated antibody and T cell immune responses contributed to cross-protection.
The incorporation of stabilized antigenic proteins into layered protein nanoparticles could be a
general vaccine strategy for different pathogens. Compared with traditional intramuscular
immunization, the MNP skin vaccination efficiently delivered antigens to skin antigen-presenting
cells, inducing robust NA- and M2e-specific antibody or cellular responses. Therefore, universal
influenza vaccines with a novel format of layered protein nanoparticles contain only antigenic
proteins of interest and are highly immunogenic, inducing robust and long-lasting immunity. The
nanoparticles are approximately the size of influenza virions and have a core of M2e displaying a
shell of conserved influenza surface antigens. The nanoparticle fabrication avoids the risk of the
instability of VLPs or other vesicle particles under osmotic stresses or changes in salt concentration
and prevents off-target immune responses against self-assembly motifs found in other protein
nanoparticle designs. The reducibility of the crosslinker DTSSP by intracellular thiols provides a
slow release of free antigenic proteins after uptake by APCs. Meanwhile, the abiotic nature of the
protein nanoparticles also enhances their amenability to a cold chain-independent storage.
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Currently, several universal influenza vaccines are in their early phases of clinical trials. We can
foresee some candidates can be tested for a later phase of efficacy trials in five years. Integrated
with novel approaches for drug delivery and controlled release, like dissolvable microneedle patchbased skin vaccination, a convenient, syringe-free and painless, self-administrated affordable
universal influenza vaccine can be available in eight to ten years.
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